Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7592033rdf:typepubmed:Citationlld:pubmed
pubmed-article:7592033lifeskim:mentionsumls-concept:C0003232lld:lifeskim
pubmed-article:7592033lifeskim:mentionsumls-concept:C0085494lld:lifeskim
pubmed-article:7592033lifeskim:mentionsumls-concept:C0002482lld:lifeskim
pubmed-article:7592033lifeskim:mentionsumls-concept:C0017953lld:lifeskim
pubmed-article:7592033lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:7592033lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:7592033lifeskim:mentionsumls-concept:C0383579lld:lifeskim
pubmed-article:7592033lifeskim:mentionsumls-concept:C0383581lld:lifeskim
pubmed-article:7592033lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:7592033pubmed:issue8lld:pubmed
pubmed-article:7592033pubmed:dateCreated1995-12-12lld:pubmed
pubmed-article:7592033pubmed:abstractTextA series of amide derivatives of natural glycopeptide A-40,926 (A), its 6B-methyl ester (MA) and 6B-decarboxy-6B-hydroxymethyl derivative (RA) were prepared with the aim of obtaining activity against glycopeptide-resistant enterococci. These compounds are structurally related to a class of amides of 34-de(acetylglucosaminyl)-34-deoxy teicoplanin which showed interesting activity against strains of Enterococcus faecalis and E. faecium highly resistant to both vancomycin and teicoplanin. Among them, RA-amides MDL 63,246 and MDL 63,042 were the most active derivatives against several Gram-positive bacteria, including VanB and VanC enterococci, and were moderately active (MIC range 0.5 approximately 64 micrograms/ml) against strains of Enterococcus for which vancomycin and teicoplanin MICs were > or = 128 micrograms/ml. The chemical rationale and the synthesis of these new series of glycopeptide derivatives are described. Preliminary in vitro data are reported and structure-activity relationships are discussed.lld:pubmed
pubmed-article:7592033pubmed:languageenglld:pubmed
pubmed-article:7592033pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7592033pubmed:citationSubsetIMlld:pubmed
pubmed-article:7592033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7592033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7592033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7592033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7592033pubmed:statusMEDLINElld:pubmed
pubmed-article:7592033pubmed:monthAuglld:pubmed
pubmed-article:7592033pubmed:issn0021-8820lld:pubmed
pubmed-article:7592033pubmed:authorpubmed-author:FerrariPPlld:pubmed
pubmed-article:7592033pubmed:authorpubmed-author:DenaroMMlld:pubmed
pubmed-article:7592033pubmed:authorpubmed-author:GoldsteinB...lld:pubmed
pubmed-article:7592033pubmed:authorpubmed-author:KurzMMlld:pubmed
pubmed-article:7592033pubmed:authorpubmed-author:MalabarbaAAlld:pubmed
pubmed-article:7592033pubmed:authorpubmed-author:ScottiRRlld:pubmed
pubmed-article:7592033pubmed:authorpubmed-author:CiabattiRRlld:pubmed
pubmed-article:7592033pubmed:authorpubmed-author:AndreiniB PBPlld:pubmed
pubmed-article:7592033pubmed:issnTypePrintlld:pubmed
pubmed-article:7592033pubmed:volume48lld:pubmed
pubmed-article:7592033pubmed:ownerNLMlld:pubmed
pubmed-article:7592033pubmed:authorsCompleteYlld:pubmed
pubmed-article:7592033pubmed:pagination869-83lld:pubmed
pubmed-article:7592033pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:meshHeadingpubmed-meshheading:7592033-...lld:pubmed
pubmed-article:7592033pubmed:year1995lld:pubmed
pubmed-article:7592033pubmed:articleTitleNew semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.lld:pubmed
pubmed-article:7592033pubmed:affiliationMarion Merrell Dow Research Institute, Lepetit Research Center, Gerenzano (Varese), Italy.lld:pubmed
pubmed-article:7592033pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7592033pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7592033lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7592033lld:pubmed